Decoy receptor 3 (DcR3) overexpression predicts the prognosis and pN2 in pancreatic head carcinoma

Zhou, Jian; Song, Shiduo; Li, Dechun; He, Songbing; Zhang, Bing; Zhu, Xinguo

doi:10.1186/1477-7819-12-52

Cited by 19 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of DcR3 protein was detected in various types of malignant tumors by our and other groups, especially in glioma, gastric, breast, liver and pancreatic cancer (Chen and Luo, 2008a;2008b;Chen et al, 2010;Huang et al, 2014;Wu et al, 2014;Zhou et al, 2014). DcR3 is also closely related to the occurrence, development and prognosis of various malignant tumors (Yang et al, 2010;Toda et al, 2013;Zhou et al, 2013;Wu et al, 2014;Zhou et al, 2014).…”

Section: Discussionsupporting

confidence: 53%

Overexpression and Clinicopathological Contribution of DcR3 in Bladder Urothelial Carcinoma Tissues

Jiang

Tang²,

Dang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Asian Pac J Cancer Prev, 15 (21), 9137-9142 IntroductionBladder urothelial carcinoma (BUC) is the fifth most common cancer worldwide, with an estimated incidence of 73, 510 cases and 14, 880 deaths in the United States in 2012. In China, the morbidity of urothelial carcinoma is 6.61/100,000, ranked the ninth in all malignant tumors (O'Keeffe et al., 2008;Yang et al., 2011;Siegel et al., 2012;Bracha et al., 2014). The decoy receptor 3 (DcR3), locating on chromosome 20q13, is a member of the tumor necrosis factor receptor (TNFR) superfamily. Previously, we have reported the overexpression of DcR3 mRNA and protein in sera or tissues of several human malignancies, including hepatocellular carcinoma, gastric carcinoma and glioma (Chen and Luo, 2008a;2008b;Chen et al., 2010;Huang et al., 2014). DcR3 has been considered as an oncogene for the aforementioned malignancies. So far, there has been only one report studying the relationship between DcR3 and urothelial carcinoma (UC). Yamana et al. (2005) investigated the amplification and protein expression of DcR3 in the tissues and cell lines of UC by using real-time quantitative PCR and immunohistochemistry in a small number of patients.However, no study has been performed to explore the relationship between DcR3 and progression of UC patients. Furthermore, the role of DcR3 on BUC has not been fully clarified. Thus, the aim of the current study was to explore

show abstract

Section: Discussionsupporting

confidence: 53%

Overexpression and Clinicopathological Contribution of DcR3 in Bladder Urothelial Carcinoma Tissues

Jiang

Tang²,

Dang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Dysregulated DcR3 expression plays an important role in tumorigenesis, metastasis and immune suppression in pancreatic head cancer [6], breast cancer [7], bladder urothelial carcinoma [8], nasopharyngeal carcinoma [9], renal carcinoma [10], glioma [11] and hepatocellular carcinoma [12, 13]. However, the contribution of DcR3 to CRC and the molecular basis for this contribution have not been fully elucidated.…”

Section: Introductionmentioning

confidence: 99%

DcR3 induces epithelial-mesenchymal transition through activation of the TGF-β3/SMAD signaling pathway in CRC

et al. 2016

View full text Add to dashboard Cite

Decoy receptor 3 (DcR3), a novel member of the tumor necrosis factor receptor (TNFR) family, was recently reported to be associated with tumorigenesis and metastasis. However, the role of DcR3 in human colorectal cancer (CRC) has not been fully elucidated. In this study, we found that DcR3 expression was significantly higher in human colorectal cancer tissues than in paired normal tissues, and that DcR3 expression was strongly correlated with tumor invasion, lymph node metastases and poor prognoses. Moreover, DcR3 overexpression significantly enhanced CRC cell proliferation and migration in vitro and tumorigenesis in vivo. Conversely, DcR3 knockdown significantly repressed CRC cell proliferation and migration in vitro, and DcR3 deficiency also attenuated CRC tumorigenesis and metastasis in vivo. Functionally, DcR3 was essential for TGF-β3/SMAD-mediated epithelial-mesenchymal transition (EMT) of CRC cells. Importantly, cooperation between DcR3 and TGF-β3/SMAD-EMT signaling-related protein expression was correlated with survival and survival time in CRC patients. In conclusion, our results demonstrate that DcR3 may be a prognostic biomarker for CRC and that this receptor facilitates CRC development and metastasis by participating in TGF-β3/SMAD-mediated EMT of CRC cells.

show abstract

“…DcR3 has been demonstrated to be a potential ovarian cancer biomarker in serum and may improve early diagnostics [22] . High expression is correlated to metastasis and worse overall survival in different cancer types [23][24][25] . Here, we showed that SI-NETs express DcR3 and patients with liver metastases display elevated serum concentrations compared to controls.…”

Section: Discussionmentioning

confidence: 99%

DcR3, TFF3, and Midkine Are Novel Serum Biomarkers in Small Intestinal Neuroendocrine Tumors

Edfeldt¹,

Daskalakis²,

Bäcklin³

et al. 2016

Neuroendocrinology

View full text Add to dashboard Cite

Small intestinal neuroendocrine tumors (SI-NETs) are amine- and peptide-producing neoplasms. Most patients display metastases at the time of diagnosis; they have an unpredictable individual disease course and the tumors are often therapy resistant. Chromogranin A and 5-hydroxyindoleacetic acid are the biomarkers clinically used most often today, but there is a great need for novel diagnostic and prognostic biomarkers and new therapeutic targets. Sixty-nine biomarkers were screened in serum from 23 SI-NET patients and 23 healthy controls using the multiplex proximity ligation assay (PLA). A refined method, the proximity extension assay (PEA), was used to analyze 76 additional biomarkers. Statistical testing and multivariate classification were performed. Immunohistochemistry and ELISA were performed in an extended cohort. Using PLA, 19 biomarkers showed a significant difference in serum concentrations between patients and controls, and PEA revealed a difference in the concentrations of 17 proteins. Multivariate classification analysis revealed decoy receptor 3 (DcR3), trefoil factor 3 (TFF3), and midkine to be good biomarkers for the disease, which was confirmed by ELISA analysis. All 3 biomarkers were expressed in tumor tissue. DcR3 concentrations were elevated in patients with stage IV disease. High concentrations of DcR3 and TFF3 were correlated to poor survival. DcR3, TFF3, and midkine exhibited elevated serum concentrations in SI-NET patients compared to healthy controls, and DcR3 and TFF3 were associated with poor survival. DcR3 seems to be a marker for liver metastases, while TFF3 and midkine may be new diagnostic biomarkers for SI-NETs.

show abstract

Decoy receptor 3 (DcR3) overexpression predicts the prognosis and pN2 in pancreatic head carcinoma

Cited by 19 publications

References 24 publications

Overexpression and Clinicopathological Contribution of DcR3 in Bladder Urothelial Carcinoma Tissues

Overexpression and Clinicopathological Contribution of DcR3 in Bladder Urothelial Carcinoma Tissues

DcR3 induces epithelial-mesenchymal transition through activation of the TGF-β3/SMAD signaling pathway in CRC

DcR3, TFF3, and Midkine Are Novel Serum Biomarkers in Small Intestinal Neuroendocrine Tumors

Contact Info

Product

Resources

About